OBI Pharma, Inc. (TPEX:4174)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
41.80
+0.10 (0.24%)
At close: Feb 26, 2026
-65.05%
Market Cap 5.50B
Revenue (ttm) 49.29M
Net Income (ttm) -2.36B
Shares Out 131.48M
EPS (ttm) -18.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 356,319
Average Volume 552,401
Open 42.00
Previous Close 41.70
Day's Range 41.60 - 42.60
52-Week Range 41.20 - 127.80
Beta 0.27
RSI 26.54
Earnings Date Mar 27, 2026

About OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of so... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4174
Full Company Profile

Financial Performance

In 2024, OBI Pharma's revenue was 62.68 million, an increase of 50.85% compared to the previous year's 41.55 million. Losses were -2.31 billion, 120.7% more than in 2023.

Financial Statements

News

There is no news available yet.